Table 2 summarizing major trials of SGLT2 inhibitors, GLP-1 receptor agonists (RAs), DPP-4 inhibitors, and RAAS inhibitors relevant to diabetes, DCM, and COVID-19. Here, GLP1R is linked to COVID-19.